Accession |
PRJCA016742 |
Title |
Phase I/II study of the tolerability, pharmacokinetics, and efficacy of SHR2554 alone or in combination with SHR3680 in patients with metastatic castration-resistant prostate cancer |
Relevance |
Medical |
Data types |
clinical,image,Metabolic,Biomarker data
|
Organisms |
Homo sapiens
|
Description |
Phase I/II study of the tolerability, pharmacokinetics, and efficacy of SHR2554 alone or in combination with SHR3680 in patients with metastatic castration-resistant prostate cancer |
Sample scope |
Multiisolate |
Release date |
2023-05-07 |
Grants |
Agency |
program |
Grant ID |
Grant title |
NA
|
|
NA
|
|
|
Submitter |
wanqiu
liang (wanqiu.liang@hengrui.com)
|
Organization |
Jiangsu Hengrui Pharmaceutical Co. LTD |
Submission date |
2023-05-05 |